Year: 2004
Type: article
Abstract: OBJECTIVE: To evaluate the effect of therapy with metformin on the lipid profile of dyslipidemic, non-diabetic patients. METHODS: We studied the subgroup of non-diabetic patients from our Lipidology / Dyslipidemia outpatient clinic who were treated with metformin as first lipid lowering drug (n=17), and evaluated the lipid profile before and 3 months after introducing the drug. We compared the baseline characteristics of this group with those of a sample of non-diabetic dyslipidemic patients treated differently. RESULTS: Three months after introducing metformin, there was a 41,8% significant reduction of triglycerides (p=0.006), as well as a 10.4% reduction of total cholesterol and a 5.9% raise of HDL cholesterol, which did not reach statistical significance. LDL cholesterol did not vary significantely.The non-diabetic patients who were treated with metformin had lower mean HDL cholesterol and higher mean triglycerides than the other non-diabetics. CONCLUSION: Metformin emerges as a good lipid-lowering drug in non-diabetic patients, particularly for patients with hypertriglyceridemia and other features of the metabolic syndrome.
Authors: Patrícia Dias, Rita Reis, Francisco Parente, J. Manuel Silva, José J. G. Moura
Language: Portuguese
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W66790374